A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Estramustine; Hydrocortisone; Ketoconazole
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Jan 2010 Biomarkers information updated
- 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2008 Checked against ClinicalTrials.gov record.